Evidence map›Paper›PMID 29596496›Full record

ArticlePloS one2018

Radiogenomics analysis identifies correlations of digital mammography with clinical molecular signatures in breast cancer.

Jose-Gerardo Tamez-Peña, Juan-Andrés Rodriguez-Rojas, Hugo Gomez-Rueda, Jose-Maria Celaya-Padilla, Roxana-Alicia Rivera-Prieto, Rebeca Palacios-Corona, Margarita Garza-Montemayor, Servando Cardona-Huerta, Victor Treviño

Abstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. A Focus on the Synergy of Radiomics and RNA Sequencing in Breast Cancer.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Radiogenomics in brain, breast, and lung cancer: opportunities and challenges.Journal of medical imaging (Bellingham, Wash.) · 2021
    Review
  12. Radiogenomics in Interventional Oncology.Current oncology reports · 2021
    Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jose-Gerardo Tamez-PeñaCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.
Juan-Andrés Rodriguez-RojasCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.
Hugo Gomez-RuedaCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.
Jose-Maria Celaya-PadillaCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.
Roxana-Alicia Rivera-PrietoCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.
Rebeca Palacios-CoronaCentro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social Ave. 2 de Abril y San Luis Potosí s/n, Col. Independencia, Monterrey, NL, México, CP.
Margarita Garza-MontemayorCentro de Cáncer de Mama, Hospital Zambrano Hellion, Av, Col. Real San Agustin, San Pedro Garza Garcia, Nuevo León, México.
Servando Cardona-HuertaCentro de Cáncer de Mama, Hospital Zambrano Hellion, Av, Col. Real San Agustin, San Pedro Garza Garcia, Nuevo León, México.
Victor TreviñoCátedra en Bioinformática, Escuela de Medicina, Tecnológico de Monterrey, Av. Morones Prieto Pte 3000, Col. Los Doctores, Monterrey, NL, México.ORCID 0000-0002-7472-9844

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In breast cancer, well-known gene expression subtypes have been related to a specific clinical outcome. However, their impact on the breast tissue phenotype has been poorly studied. Here, we investigate the association of imaging data of tumors to gene expression signatures from 71 patients with breast cancer that underwent pre-treatment digital mammograms and tumor biopsies. From digital mammograms, a semi-automated radiogenomics analysis generated 1,078 features describing the shape, signal distribution, and texture of tumors along their contralateral image used as control. From tumor biopsy, we estimated the OncotypeDX and PAM50 recurrence scores using gene expression microarrays. Then, we used multivariate analysis under stringent cross-validation to train models predicting recurrence scores. Few univariate features reached Spearman correlation coefficients above 0.4. Nevertheless, multivariate analysis yielded significantly correlated models for both signatures (correlation of OncotypeDX = 0.49 ± 0.07 and PAM50 = 0.32 ± 0.10 in stringent cross-validation and OncotypeDX = 0.83 and PAM50 = 0.78 for a unique model). Equivalent models trained from the unaffected contralateral breast were not correlated suggesting that the image signatures were tumor-specific and that overfitting was not a considerable issue. We also noted that models were improved by combining clinical information (triple negative status and progesterone receptor). The models used mostly wavelets and fractal features suggesting their importance to capture tumor information. Our results suggest that molecular-based recurrence risk and breast cancer subtypes have observable radiographic phenotypes. To our knowledge, this is the first study associating mammographic information to gene expression recurrence signatures.

Indexed as

AdultBreastBreast NeoplasmsFemaleHumansMammographyMiddle AgedNeoplasm Recurrence, LocalProspective StudiesRisk Assessment

Identifiers

PMID29596496
PMCPMC5875760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.